ABSTRACT
Differentiated thyroid cancer (DTC) is prone to relapse and metastasize. In addition to thyroglobulin (Tg) and its antibodies, ultrasound and 131I whole-body scan (WBS), 18F-FDG PET/CT gains more use in the setting of recurrent or metastatic DTC and shows promise. This article mainly reviews the value of 18F-FDG PET/CT in the location of recurrent or metastasized DTC with negative 131I WBS but positive Tg ( 131I WBS-/Tg+ ), evaluating their differentiation, predicting the prognosis, guiding 131I treatment and its value in restaging DTC with moderate and high risk of relapse and guiding treatment decision.
ABSTRACT
The clinical,molecular and pathological features of pediatric differentiated thyroid cancer (DTC),and the advances in its surgery,postoperative staging,risk stratification,131I treatment were summarized based on the management Guidelines for children with thyroid nodules and DTC from the American Thyroid Association (ATA)
ABSTRACT
As a type of neuroendocrine tumors, neuroblastoma (NB) is the most common extra-cranial solid tumor of childhood.123/131I-MIBG scintigraphy is a standard imaging modality in staging and evaluating therapeutic effect of pediatric NB with high accuracy.131I-MIBG treatment is effective for children with high-risk and relapsed/refractory NB.Combined with chemotherapy, stem cell transplantation, 131I-MIBG treatment shows efficacy in decreasing the relapse of pediatric NB.This review summarizes the application of MIBG scintigraphy and 131I-MIBG treatment for pediatric NB.
ABSTRACT
As a type of neuroendocrine tumors,neuroblastoma (NB) is the most common extra-cranial solid tumor of childhood.123/131I-MIBG scintigraphy is a standard imaging modality in staging and evaluating therapeutic effect of pediatric NB with high accuracy.131I-MIBG treatment is effective for children with high-risk and relapsed/refractory NB.Combined with chemotherapy,stem cell transplantation,131I-MIBG treatment shows efficacy in decreasing the relapse of pediatric NB.This review summarizes the application of MIBG scintigraphy and 131I-MIBG treatment for pediatric NB.
ABSTRACT
Objective To investigate the effect of postoperative TSH suppression on bone mineral density (BMD) in postmenopausal women with DTC.Methods Postmenopausal women with postoperative DTC underwent thyroid residual ablation or 131I treatment for metastases at Xin Hua Hospital between September 2009 and December 2014 were enrolled and followed for 2 years.They were divided into suppressive TSH group (median TSH<0.30 mU/L;group 1) and non-suppressive group (median TSH≥0.30 mU/L;group 2).Lumber 1-4 BMD levels (T scores) were measured by a dual energy X-ray absorptiometry bone densitometer at baseline,1 year and 2 years after treatment.All patients had calcium and vitamin D supplementation after TSH suppression.The T scores were compared with Mann-Whitney u test and Kruskal-Wallis test.Results A total of 126 patients were enrolled and followed up for 2 years,including 65 with average age (57.65±6.65) years in group 1 and 61 with average age (56.19±7.17) years in group 2.The T scores in group 1 and group 2 at baseline were-1.70(-2.30,-0.55) and-1.30(-2.10,-0.30) (z=-1.660,P> 0.05).The difference of T scores was significant in group 1 at baseline,1-year follow-up and 2-year follow-up (-2.25(-2.48,-0.83),-1.95(-2.70,-0.60);H=6.244,P<0.05),but not significantly different in group 2 (H=1.102,P>0.05).The T values were different between the 2 groups both in 1-year follow-up and 2-year follow-up (z values:-2.170,-2.160,both P<0.05).Conclusions TSH suppression significantly increases the risk of postoperative osteoporosis.The BMD should be followed up annually in postmenopausal DTC patients.